Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Squamous Cell Carcinoma of the Head and Neck: early-phase trial registry
7 of 30 indexed Squamous Cell Carcinoma of the Head and Neck trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 7 currently recruiting · #519 of 28,707 conditions by registered trial count
Squamous Cell Carcinoma of the Head and Neck: 30 US clinical trials tracked, 7 recruiting.
Squamous Cell Carcinoma of the Head and Neck is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most active sponsor is Seagen, a wholly owned subsidiary of Pfizer, running 2 of these trials.
Enrollment posture brief
Registry condition squamous-cell-carcinoma-of-the-head-and-neck
OPEN 7 | RECR 23% | LATE 2 | EARLY 25 | RANK #519 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Alzheimers Disease (23% recruiting · 150 trials)
Squamous Cell Carcinoma of the Head and Neck lists 7 open slots (23% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Squamous Cell Carcinoma of the Head and Neck on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Squamous Cell Carcinoma of the Head and Neck is recruiting below its size-band peers.
7 of 30 indexed trials (23.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Squamous Cell Carcinoma of the Head and Neck trials is spread across many organizations.
Seagen, a wholly owned subsidiary of Pfizer accounts for 2 of 30 trials (6.7%). 26 distinct sponsors appear on at least one study for this condition label.
-
Most Squamous Cell Carcinoma of the Head and Neck trials plan to enrol fewer than 100 people.
Median target enrolment is 51 among the 30 trials that report a genuine target (sentinel values excluded). 21 of those (70%) plan for fewer than 100 participants.
-
Squamous Cell Carcinoma of the Head and Neck research is mostly interventional.
28 interventional and 2 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05208762
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18
NCT04787042
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Iovance Biotherapeutics
NCT03645928
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Janux Therapeutics
NCT05783622
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
National Cancer Institute (NCI)
NCT06223568
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
Emory University
NCT03690986
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
VLP Therapeutics
NCT06736379
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
AstraZeneca
NCT04590963
A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study
University of Chicago
NCT02841748
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05983133
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
Dana-Farber Cancer Institute
NCT03341936
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck
Assuntina G. Sacco, MD
NCT02769520
Ipilimumab for Head and Neck Cancer Patients
Providence Health & Services
NCT02812524
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
University of California, San Diego
NCT03646461
Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
AstraZeneca
NCT02551159
A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)
Bristol-Myers Squibb
NCT05068609
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Xencor
NCT03517488
Saliva-based Detection of CD44
Joseph Califano
NCT03148665
Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma
Acerta Pharma
NCT02454179
Priming Immunotherapy in Advanced Disease With Radiation
John L. Villano, MD, PhD
NCT03313804
Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
Akamis Bio
NCT02636036
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Arcus Biosciences
NCT03629756
Study of Unilateral Neck Irradiation in Patients With SCC of the Head and Neck
Beth Israel Medical Center
NCT00206752
Cabazitaxel - PF Induction Chemotherapy
Krzysztof Misiukiewicz
NCT01379339
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
NCT01612351
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
Robert Ferris
NCT01218048
De-Escalation Therapy for Human Papillomavirus Negative Disease
University of Chicago
NCT03944915
Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck
H. Lee Moffitt Cancer Center and Research Institute
NCT02158234
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT03758781
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
Seagen
NCT03245736
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 12 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Squamous Cell Carcinoma of the Head and Neck records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Squamous Cell Carcinoma of the Head and Neck trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Squamous Cell Carcinoma of the Head and Neck page
30 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Squamous Cell Carcinoma of the Head and Neck trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Seagen, a wholly owned subsidiary of Pfizer sponsors the most Squamous Cell Carcinoma of the Head and Neck trials on record, review their full trial history before evaluating a specific study. See Seagen, a wholly owned subsidiary of Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Squamous Cell Carcinoma of the Head and Neck condition card totals 30 registered trials; most-linked intervention Nivolumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.